Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

Biosplice Therapeutics Stock

Q: How to sell Biosplice Therapeutics stock?

If you hold private company shares of Biosplice Therapeutics - whether as an employee or an early investor - Forge can help you sell them. 1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have. 2. Indicate your interest to sell your Biosplice Therapeutics stock on our platform. 3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

biosplice.comHealthcare / BioTech & PharmaFounded: 2008

Biosplice Therapeutics is developing therapies through alternative pre-mRNA splicing, which can allow for the elimination of harmful proteins. The company's current pipeline focuses on osteoarthritis and oncology. Biosplice Therapeutics was founded in 2008 by Osman Kibar Ph.D., Dennis Carson, Richard Schwab, and John Hood Ph.D. and is headquartered in San Diego, CA.

Buy or sell Biosplice Therapeutics stockLearn more about Biosplice Therapeutics IPO

OverviewFinancingsValuation

Enterprise Value

Access Biosplice Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Biosplice Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Biosplice Therapeutics investors also invested in these private companies

Vickers Venture Partners

Biosplice Therapeutics, Aardvark Therapeutics, Chooch AI, Zanbato

Vast Ventures

Diamond Foundry, Tala, Biosplice Therapeutics, Super Coffee, Asapp, Higher Ground, Yieldmo, RapidSOS, Nomad

Forepoint Capital Partners

Precision Neuroscience, Biosplice Therapeutics

Polar Light Ventures

Biosplice Therapeutics

aMoon Fund

Biosplice Therapeutics, Ultima Genomics, Better Life Partners

SymBiosis Capital Management

Biosplice Therapeutics, Aardvark Therapeutics, FogPharma, Neurona Therapeutics, Ensoma, Endeavor BioMedicines, Saliogen Therapeutics

Team

Management Team

Cevdet Samikoglu

Chief Executive Officer & Board Member

Erich Horsley

Chief Financial Officer & Chief Business Officer

Scott Bulcao

Chief Legal Officer

Osman Kibar Ph.D

Co-Founder & Executive Chairman

Yusuf Yazici MD

Chief Medical Officer

Board Members

Chidozie Ugwumba

SymBiosis Capital Management

Gur Roshwalb MD

aMoon Fund

Joy Ghosh Ph.D

Eventide Asset Management

Kyle Rasbach Ph.D

Eventide Asset Management

Biosplice Therapeutics stock FAQs

Can you buy Biosplice Therapeutics stock?

As Biosplice Therapeutics is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Biosplice Therapeutics, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy Biosplice Therapeutics stock?

To invest in a private company like Biosplice Therapeutics through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Biosplice Therapeutics stock?

Yes, you may be able to sell your Biosplice Therapeutics stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Biosplice Therapeutics stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Biosplice Therapeutics stock on our platform.
Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is Biosplice Therapeutics a public company?

No, Biosplice Therapeutics is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Biosplice Therapeutics’ stock price?

Biosplice Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Biosplice Therapeutics’ private market stock price with Forge Data.

What is Biosplice Therapeutics’ stock ticker symbol?

Biosplice Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Longevity Technology News 12/22/2022

Biosplice announces data from osteoarthritis clinical trial – and the initiation of new phase 3 trial

Biosplice Therapeutics, a clinical-stage biotech company pioneering first-in-class small molecule therapeutics, has announced potential structure-modifying highlights from an ongoing long-term extension study for its knee osteoarthritis (OA) drug candidate, lorecivivint.

Pharmaceutical Technology 10/31/2022

The osteoarthritis market is expected to increase to $3.8bn in 2031

The osteoarthritis (OA) market was valued at $2.5 billion in the 7MM (seven major markets) in 2021, and is expected to increase to $3.8 billion in 2031, at a compound annual growth rate (CAGR) of 4.4%.

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.